Lipika Goyal, MD, on Treating Intrahepatic Cholangiocarcinoma With Futibatinib

April 16, 2021 By The ASCO Post Staff

Lipika Goyal, MD, of Massachusetts General Hospital, discusses phase II results of the FOENIX-CCA2 trial, which explored the clinical benefit of futibatinib, an FGFR1–4 inhibitor, tested in patients with intrahepatic cholangiocarcinoma that harbored FGFR2 gene fusions or other rearrangements (Abstract CT010).

Related Content